October 26th, 2011
Danish Study Clarifies VTE Risk Associated with Newer Progestogens in Oral Contraceptives
Larry Husten, PHD
A large new study from Denmark provides the best evidence yet that third-generation oral contraceptives (OCs) containing drospirenone, desogestrel, or gestodene (sometimes used to treat dysmenorrhea) are associated with twice the risk for venous thromboembolism (VTE) as second-generation OCs containing levonorgestrel. In a paper published in BMJ, Øjvind Lidegaard and colleagues analyzed data from national registries containing more […]
